Header SAKK 06/14

Immunotherapy with BCG-VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after conventional BCG therapy (trial SAKK 06/14)

Immunotherapy with BCG-VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after conventional BCG therapy (trial SAKK 06/14)

In trial SAKK 06/14 we wanted to find out how safe, well tolerated, and effective a treatment with BCG-VPM1002BC is in bladder cancer.

Non-muscle invasive bladder cancer is usually removed by surgery, which is followed by what is known as BCG therapy, special bacteria (Bacillus Calmette-Guérin, BCG) are instilled into the bladder, triggering an immune response in the bladder mucosa and thereby helping to combat the cancer. A promising new, genetically modified BCG strain termed "VPM1002BC" triggers a modified immune response that may be more effective for treating bladder cancer.